aTyr Pharma Ends Kyorin Collaboration; Regains Global Rights to Efzofitimod

What Happened

• aTyr Pharma announced that Kyorin Pharmaceutical Co., Ltd. elected to terminate their collaboration and license agreement (the "Kyorin Agreement"). Kyorin gave notice on May 12, 2026, and the parties executed a Termination Agreement dated July 30, 2026 that set the termination date as July 30, 2026.
• Under the Termination Agreement the license to Kyorin ceased, ancillary agreements were terminated, and wind‑down activities were agreed. As a result, exclusive rights to develop and commercialize efzofitimod in Japan reverted to aTyr, and aTyr now holds the right to develop and commercialize efzofitimod globally.

Key Details

• Notice of termination received: May 12, 2026 (Kyorin elected to terminate without cause).
• Termination Agreement executed: July 30, 2026; Termination Date: July 30, 2026.
• Effect: Kyorin’s license ended; exclusive Japan rights reverted to aTyr and global development/commercialization rights to efzofitimod returned to aTyr.
• The Termination Agreement (material terms summarized) is filed as Exhibit 99.1 to the 8-K.

Why It Matters

• Regaining global rights to efzofitimod gives aTyr full control over future development, regulatory strategy, and potential commercialization decisions for the asset.
• This change could affect aTyr’s partnering strategy, development timeline and future revenue opportunities tied to efzofitimod; the filing documents agreed wind‑down terms but does not disclose any new financial commitments or milestone payments in the 8-K.
• Investors should review the Termination Agreement (Exhibit 99.1) and aTyr’s subsequent disclosures for details on next steps, development plans, potential costs, or new collaborations.